Skip to content

Clinical trials

Completed Mood Disorders trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Mood Disorders Status: Completed Country / region: United States Clear all

195 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
20014
20024
20033
200410
20054
20069
20074
200811
20094
20108
20119
20128
20134
201412
20158
20164
201712
20184
201911
202012
202110
20225
20234
20244
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed195

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Mental Health (NIMH)34
University of Michigan8
VA Office of Research and Development8
Massachusetts General Hospital7
New York State Psychiatric Institute6
Otsuka Pharmaceutical Development & Commercialization, Inc.6
Stanford University6
University of North Carolina, Chapel Hill6
Luye Pharma Group Ltd.5
University of Pittsburgh5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Mood Disorders195
Major Depressive Disorder57
Depressive Disorder48
Bipolar Disorder46
Anxiety Disorders43
Mental Disorders42
Psychotic Disorders12
Substance-Related Disorders11
Schizophrenia9
Stress Disorders, Post-Traumatic9

Trials

Showing 1 to 25 of 195. Each trial links to its page on Pharma Observatory.

95 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.